Try our mobile app

Four-Year Biktarvy® Data Presented at IAS 2021 Demonstrate High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults

Published: 2021-07-17 10:01:00 ET
<<<  go to GILD company page

– 99% of Participants Achieved and Maintained an Undetectable Viral Load With Biktarvy in Pooled Analysis of 192-Week Data From Open-Label Extension Period of Two Phase 3 Trials in Treatment-Naïve Adults –

– 72-Week Data From the BRAAVE Study Demonstrate 99% of Black Adults Who Are Virologically Suppressed and Switched to Biktarvy From a Standard Regimen Achieved and Maintained an Undetectable Viral Load –

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced a pooled analysis of a 48-week open-label extension of two Phase 3 studies (Study 1489 and Study 1490) shows 99% of participants who initiated treatment with Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) maintained an undetectable viral load (HIV-1 RNA